| ISIN | AT0000A1FNT0 |
|---|---|
| Valor Number | 28871817 |
| Bloomberg Global ID | |
| Fund Name | DSC Equity Fund – Healthcare A|A |
| Fund Provider |
Dreyfus Söhne & Cie AG, Banquiers
Aeschenvorstadt 16 | Postfach 4051 Basel Schweiz Phone: +41 61 286 66 66 Web: https://www.dreyfusbank.ch |
| Fund Provider | Dreyfus Söhne & Cie AG, Banquiers |
| Representative in Switzerland |
Dreyfus Söhne & Cie AG, Banquiers Basel |
| Distributor(s) |
Dreyfus Söhne & Cie AG, Banquiers Basel |
| Asset Class | Equities |
| EFC Category | |
| Distribution Policy | Distribution |
| Home Country | Austria |
| Issuing Condition | The fund does not charge any issuing commission and/or fees (units are issued at the NAV) |
| Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
| Investment Strategy *** | N/A |
| Peculiarities |
| Current Price * | 212.20 CHF | 19.12.2025 |
|---|---|---|
| Previous Price * | 212.36 CHF | 18.12.2025 |
| 52 Week High * | 237.48 CHF | 04.03.2025 |
| 52 Week Low * | 186.68 CHF | 08.08.2025 |
| NAV * | 212.20 CHF | 19.12.2025 |
| Issue Price * | 218.57 CHF | 19.12.2025 |
| Redemption Price * | 212.20 CHF | 19.12.2025 |
| Closing Price * | ||
| Indicative Minimum Price | ||
| Fund Assets *** | 41,523,502 | |
| Unit/Share Assets *** | 39,777,610 | |
| Trading Information SIX | ||
| YTD Performance | -5.22% |
30.12.2024 - 19.12.2025
30.12.2024 19.12.2025 |
|---|---|---|
| 1 month | +0.83% |
19.11.2025 - 19.12.2025
19.11.2025 19.12.2025 |
| 3 months | +9.39% |
19.09.2025 - 19.12.2025
19.09.2025 19.12.2025 |
| 6 months | +7.68% |
20.06.2025 - 19.12.2025
20.06.2025 19.12.2025 |
| 1 year | -4.05% |
19.12.2024 - 19.12.2025
19.12.2024 19.12.2025 |
| 2 years | +0.17% |
19.12.2023 - 19.12.2025
19.12.2023 19.12.2025 |
| 3 years | -7.76% |
19.12.2022 - 19.12.2025
19.12.2022 19.12.2025 |
| 5 years | +0.01% |
21.12.2020 - 19.12.2025
21.12.2020 19.12.2025 |
| Equity Participation Rate in % | 96.10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Real Estate Rate in % | 0.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI Date | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| iShares MSCI Wld HlthCrSect AdvcdETF$Inc | 9.26% | |
|---|---|---|
| Eli Lilly and Co | 7.93% | |
| Johnson & Johnson | 6.84% | |
| AstraZeneca PLC | 4.32% | |
| AbbVie Inc | 3.86% | |
| Abbott Laboratories | 3.68% | |
| Merck & Co Inc | 3.63% | |
| UnitedHealth Group Inc | 3.45% | |
| Thermo Fisher Scientific Inc | 3.34% | |
| Roche Holding AG | 3.05% | |
| Last data update | 30.11.2025 | |
| TER | 1.52% |
|---|---|
| TER date | 31.10.2025 |
| Performance Fee *** | |
| PTR | |
| Max. Management Fee *** | 1.50% |
| Ongoing Charges *** | 1.49% |
|
SRRI ***
|
|
| SRRI date *** | 30.11.2025 |